ArticleFrontiers in neurology2025

Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.

Michail Vikelis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.